CDMOWacker Chemie AG opens €100m RNA manufacturing siteWith the opening of a production centRE for RNA vaccines and therapeutics, German CDMO Wacker Biotech is expanding its expertise in the field of RNA active ingredients. more ➔
CROConsortium led by Evotec enters obesity drug spaceDrug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseas … more ➔
Lab automationSemarion Ltd. wins Ignite SME award at SLAS EuropeUK-based Semarion Ltd. was honoured as the most innovative company in the field of laboratory automation at SLAS Europe 2024 in Barcelona. more ➔
acquisitionMSD grabs Eyebiotech Ltd for US$1.3bn upfrontUS pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones. more ➔
SLASLab automationSLAS Europe 2024 honours products with most impactSwiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector. more ➔
VirologyHornet Therapeutics reports first data of EBV-triggered disease blocker Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease. more ➔
AstraZeneca puts step into obesity marketSwiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc. more ➔
financingLabGenius raises £35m to expand its antibody discovery platformLondon-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round. more ➔
FinancingSeed financing for Cellugy A/SDanish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products. more ➔
Roche, Herzog&De MeuronObesityObesity: Roche with first clinical data after US$2.7bn dealObesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data. more ➔
SLAS
Roche, Herzog&De Meuron